Plasma levels of apomorphine following intravenous, intraperitoneal and oral administration to mice and rats.
Clinical use of the potent dopaminergic partial-agonist apomorphine (APO) in a wide variety of neuropsychiatric disorders is hampered by a lack of data concerning tissue/plasma levels following various routes of administration. In the present experiments, plasma levels were assessed at various times up to 4 hours after APO administration IV, IP, and PO to mice and rats. Plasma levels of total radioactivity after PO administration of [3H]-APO were 50 to 65% of those seen after IV administration, but brain levels were almost undetectable after PO administration. Organic solvent-extractable concentrations of tritium-labelled material after IV and IP administration of [3H]-APO to mice were significantly lower than the levels of total radioactivity, while after PO administration, these concentrations were minimal. Similar results were observed in rats following IV and PO administration of [3H]-APO.
D000284:Administration, Oral; D000327:Adsorption; D000537:Aluminum Oxide; D000818:Animals; D001058:Apomorphine / Q000008:administration & dosage / Q000097:blood* / Q000378:metabolism; D001682:Biological Availability; D001921:Brain / Q000378:metabolism; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D008722:Methods; D051379:Mice; D051381:Rats
D000537:Aluminum Oxide; D001058:Apomorphine